Portal de Periódicos da CAPES

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

2021; Springer Science+Business Media; Volume: 23; Issue: 2 Linguagem: Inglês

10.1208/s12248-021-00574-0

1550-7416

Julianne D. Twomey, Baolin Zhang,

Pancreatic and Hepatic Oncology Research

Abstract Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many cancer indications. This review provides an update on ICIs approved by the Food and Drug Administration (FDA), with focus on monoclonal antibodies that target the programmed cell death 1 (PD-1) or its ligand, PD-1 ligand 1 (PD-L1), including information on their clinical indications and associated companion diagnostics. The information is further discussed with strategies for identifying predictive biomarkers to guide the clinical use of PD-1/PD-L1-targeted therapies.